Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory ...

14 November 2026 · By · Wire by Fusion42

Published

14 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at firstwordpharma.com →

◆ Verified

Fusion42 · 14 November 2026 · Fusion42 review

Cingulate Inc. has substantially completed manufacturing work to address the FDA's CMC requests for its ADHD treatment CTx-1301 and plans to resubmit the NDA between December 2026 and January 2027. The FDA's prior Complete Response Letter raised no clinical safety or efficacy concerns. The company has increased cash reserves and is funding commercial readiness efforts.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

Your ADHD drug now faces a clearer path through FDA red tape with key manufacturing gaps closed. You need to prepare your commercial plans now as approval could come within months.

◆ Coverage

2 sources · 14 Nov 2026

◆ Related on Wire

◆ Topics

Biotechnda-resubmissionfda-approvaladhd-treatmentbiopharmacmc-compliance